The regulatory and market access landscape for biosimilars is constantly evolving. For a company seeking to develop a biosimilar for multiple markets, keeping track of the similarities and differences between countries can be a significant challenge. The Access & Reimbursement Landscape allows rapid assessment of key market access parameters in the United States, EU5, Japan, Canada, and key emerging markets.
Questions answered
Key markets covered
France, Germany, Italy, Spain, United Kingdom, United States, Japan, Australia, Brazil, Canada, and China.
Key companies mentioned
Key drugs mentioned